Oxford Biomedica H1 Loss Widens to £36.2m
Oxford Biomedica H1 Loss Widens to £36.2m
Anonymous
Key Points
1
Oxford Biomedica’s non-risk-adjusted pipeline grew about 30% year over year to $713 million, while the company reported reduced reliance on large clients and strong repeat business.
2
Gross margin fell to 37% from 43% because of project-mix effects and one-off comparatives, despite the improvement in adjusted operating EBITDA loss.
3
Oxford Biomedica said client activity at its Durham, North Carolina, site is expected to increase in the second half after remedial work related to earlier delays.
4
Finance income fell to £1.8 million from £4.4 million, while finance costs rose to £9.0 million from £6.9 million; diluted loss per share consequently widened to 30.39 pence from 25.35 pence.
5
Chief Executive Frank Mathias said the company’s operational focus remained on “disciplined execution and cost control” while it works to increase utilisation and progress toward its 2030 revenue and sustainable-profitability ambitions.
Oxford Biomedica, a cell and gene therapy manufacturer, grew first-half revenue to £80 million—up 9% year over year—but its pretax loss widened sharply to £36.2 million from £26.0 million MarketScreener. The company added 17 new clients during the period, bringing its total portfolio to 59 programmes across 50 customers, yet higher manufacturing costs and a £7.6 million asset write-down offset the commercial gains.
Despite the widening loss, Oxford Biomedica held firm on its full-year revenue guidance of £180 million to £200 million and reiterated a 2030 ambition to reach £500 million in sales MarketScreener. The company's Durham, North Carolina, manufacturing facility became operational and completed its first regulatory-compliant production run, signaling progress toward higher output and profitability.
Rising Costs Squeeze Margins Despite Revenue Growth
Cost of sales jumped 22% to £50.7 million as Oxford Biomedica ramped up manufacturing operations MarketScreener. Gross margin fell to 37% from 43% because of the project mix and one-off comparisons, even though adjusted operating EBITDA loss improved to £2.5 million from £3.9 million. The company is betting that new Durham capacity and better client mix will restore profitability.
Pipeline Growth and Diversified Customer Base
Oxford Biomedica's non-risk-adjusted pipeline grew roughly 30% year over year to $713 million, signaling strong long-term demand MarketScreener. The company reduced reliance on large clients and saw strong repeat business, a positive sign that its relationships are deepening. Its backlog stands at £193 million, with £168 million of expected 2026 revenue already covered by signed contracts.
Finance Costs Rise as Losses Widen Per Share
Finance costs climbed to £9.0 million from £6.9 million, while finance income fell sharply to £1.8 million from £4.4 million MarketScreener. As a result, diluted loss per share widened to 30.39 pence from 25.35 pence. Chief Executive Frank Mathias emphasized the need for "disciplined execution and cost control" as the company works to boost manufacturing utilization and move toward sustainable profitability.
Durham Facility Ready to Drive 2026 Ramp
Oxford Biomedica's new North Carolina manufacturing site is expected to see a sharp rise in client activity during the second half of 2026 after remedial work addressed earlier delays MarketScreener. The facility's first GMP-certified batch marks a critical milestone for scaling production. The company targets 25% to 30% revenue growth in 2027 as it leverages the new capacity and pursues its £500 million revenue goal by 2030.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
42
Reach
56
A
AnonymousAuthor
